Blog

Scroll For More

FDA Issues Warning Regarding Transvaginal Mesh

According to a recent Food and Drug Administration (FDA) warning, transvaginal placement of surgical mesh might not be the best treatment option in patients suffering from pelvic organ prolapse (POP) or stress urinary incontinence (SUI). Transvaginal mesh is a type of surgical mesh that is permanently implanted in patients suffering from POP or SUI to strengthen the weakened vaginal wall. Although doctors routinely use transvaginal mesh to treat such conditions, the FDA warns that thousands of women are at risk of developing serious health complications despite the fact that much safer and similarly effective alternatives exist.

The FDA reports that the most common complication associated with the use of transvaginal mesh is mesh erosion through the vagina, commonly referred to as exposure, protrusion, or extrusion. Women who have undergone treatment involving the use of transvaginal mesh should be aware of the variety of symptoms such as pain, infection, bleeding, discomfort during sex, organ perforation, urinary problems, and mesh contraction. Women who experience these complications might require unnecessary future surgeries, but surgery may not be enough to treat these problems in all women.

If you or someone you know has suffered complications from transvaginal mesh surgery, contact the attorneys at Abraham, Watkins, Nichols, Agosto, Aziz & Stogner by calling 713-396-3964.

Archives

FindLaw Network
Text
#TXTFREETX
Learn more about the Annual Text Free Texas Scholarship Contest
360

VIRTUAL OFFICE TOUR
Take a virtual tour of our office online!

Call
CONTACT US TODAY!
Get Your Free Case Review